Get Support

Learn Mode

ABBV - AbbVie Inc

455

$215.06

-$2.43 (-1.117%)

4/1/26, 3:35 PM

3.63/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

ABBV

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$386.54B

Industry

Biotechnology

EPS (TTM)

$2.36

P/E (TTM)

92.34

Div & Yield

$6.92 (3.22%)

FCF Payout Ratio

69.81%

P/S (TTM)

6.32

P/B

0.00

Diluted Shares

1.78B

Ex-Dividend

2026-04-15

Next Earnings

04-24

Forward P/E

14.22

Payout Ratio

297.13%

P/FCF (TTM)

21.70

FCF Yield

4.61%

Earnings Yield

1.08%

52 Week Range

Score Card

Explore Scores Tab

3.63

Good

AbbVie Inc has grown revenue at 8.57% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 29.13%, which suggests the company is very profitable.

Valuation Model

Key Score

2.00

Bad

Management

1.00

Very Bad

Growth

3.00

Average

Profitability

4.00

Good

Fin. Health

5.00

Very Good

Dividends

3.00

Average

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 15:06:03

Form ARS

Unknown Form Type

Filed on 2026-03-23 17:09:41

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-23 17:01:40

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-23 16:59:27

Form 4/A

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-11 17:00:20

Form PRE 14A

Unknown Form Type

Filed on 2026-03-09 16:31:02

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:05:44

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-06 17:04:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 17:02:27

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-04 16:59:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:14:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:12:11

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$344.40

60.1%

Avg:

$256.47

19.3%

Low:

$189.76

-11.8%

(% change is relative to the current stock price: $215.06)

Analyst Recommendations

Go to Analyst Tab

3.87

Good

18%

Strong Buy (7)

51%

Buy (20)

31%

Hold (12)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.abbvie.com/
Address
1 N Waukegan Rd, North Chicago ILLINOIS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1551152

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

IPO Date

2013-01-02

Industry

Biotechnology

Total Employees

57,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences